Interní Med. 2006; 8(7): 348-351

Depression, metabolic syndrome and diabetes mellitus

MUDr. Jiří Podlipný1, MUDr. Zdeněk Hess2
1 Psychiatrická klinika FN a LF UK v Plzni
2 II. interní klinika LF UK a FN, Plzeň

We usually focus our attention on adverse events of antipsychotic medication when thinking of metabolic syndrome and type 2 diabetes in psychiatry. We want to show another important issue in the following article, which is the increased comorbidity of depression and type 2 diabetes. Depression usually precedes the development of type 2 diabetes and therefore it is necessary to monitor the metabolic risk factors in depressive patients.

Keywords: Keywords: depression, metabolic syndrome, diabetes.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Podlipný J, Hess Z. Depression, metabolic syndrome and diabetes mellitus. Interní Med. 2006;8(7):348-351.
Download citation

References

  1. Akiskal HS. Mood Disorders: Introduction and Overview. In: Kaplan & Sadock´s Comprehensive Textbook of Psychiatry Seventh Edition (on CD), kapitola 14.1, podkapitola Modern Era., L. Williams & Wilkins, Philadelphia, 2000.
  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC, American Psychiatric Association, 1994.
  3. Eaton WW, Mengel M, Mengel L, Larson D, Campbell R, Montague RB. Psychosocial and psychopathologic influences on management and control of insulin-dependent diabetes. Int. J. Psychiatry Med. 1992; 22 (2): 105-117. Go to original source... Go to PubMed...
  4. Eaton WW, Armenian HK, Gallo JJ, Pratt L, Ford D. Depression and risk for onset of Type II diabetes: a prospective, populationbased study. Diabetes Care. 1996; 19 (10): 1097-1102. Go to original source... Go to PubMed...
  5. Eaton WW. Epidemiologic evidence on the comorbidity of depression and diabetes. Journal of Psychosomatic Research. 2002; 53 (4): 903-906. Go to original source... Go to PubMed...
  6. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000; 61 (11): 863-867. Go to original source... Go to PubMed...
  7. Halford JC, Harrold JA, Lawton CL, Blundell JE. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets. 2005; 6 (2): 201-213. Go to original source... Go to PubMed...
  8. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62 (1): 19-28. Go to original source... Go to PubMed...
  9. Chiba M, Suzuki S, Hinokio Y, Hirai M, Satoh Y, Tashiro A, Utsumu A, Awata T, Hongo M, Toyota T. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism 2000; 49 (9): 1145-1149. Go to original source... Go to PubMed...
  10. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome 2005. K dispozici na internetu: http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf.
  11. Kawakami N, Takatsuka N, Hiroyuki S, Hiroshi I. Depressive symptoms and occurence of type 2 diabetes among japanese men. Diabetes Care. 1999; 22: 1071-1076. Go to original source... Go to PubMed...
  12. Kylin E. Studien über das Hypertonie-Hyperglykämie-Hyperurikämiesyndrom. Zentralblatt für Innere Medizin 1923; 44: 105-127.
  13. Nichols GA, Brown JB. Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. Diabetes Care. 2003; 26: 744-749. Go to original source... Go to PubMed...
  14. Palinkas LA, Lee PP, Barret-Connor E. A prospective study of type 2 diabetes and depressive symptoms in the elderly: The Rancho Bernardo Study. Diabet. Med. 2004; 21: 1185-1191. Go to original source... Go to PubMed...
  15. Podlipný J, Hess Z, Rosolová H, Petrlová B, Topolčan O, Holubec L: Vliv léčby sertralinem na metabolický syndrom inzulínové rezistence - výsledky studie. Česká psychiatrie a svět. Praha, Galén, 2004: 171-172 s.
  16. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607. Go to original source... Go to PubMed...
  17. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol. Psychiatry 2003; 54: 227-240. Strik, JJ, Denollet J, Lousberg R, et al. Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction. J Am Coll Cardiol 2003; 42: 1801-1807. Go to original source... Go to PubMed...
  18. Svacina S. Our experience with antidepressant treatment in the obese and type 2 diabetics. Prague Med Rep. 2005; 106 (3): 291-296. Go to PubMed...
  19. Svačina Š, Owen K. Syndrom inzulínové rezistence. Triton, Praha, 2003: 16 s.
  20. Svačina Š. Obezita a psychofarmaka. Triton, Praha, 2002: 35 s.
  21. Švestka J, in: Höschl C, Libiger J, Švestka J. Psychiatrie. Tigis, Praha, 2004: 714 s.
  22. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143-3421. Go to original source...
  23. van Praag HM, Leijnse B: Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of antidepressive drugs of the hydrazine type. Psychopharmacol 1965; 8: 67-78. Go to original source... Go to PubMed...
  24. Winokur A, Meislin G, Phillips J, et al. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry. 1988; 145: 325-330. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.